

Should the economic pillar be included in national, European or global consensuses concerning *Helicobacter pylori* infection treatments?

Christos Liatsos^a, Apostolis Papaefthymiou^a,
Sotirios D. Georgopoulos^b, Jannis Kountouras^c

401 Army General Hospital of Athens; Paleo Faliron Hospital, Athens; Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece

The Hellenic *Helicobacter pylori* (*H. pylori*) consensus working group published the first national guidelines regarding the *Helicobacter pylori* infection, to assist physicians in their daily clinical practice [1]. With regard to *H. pylori* treatment, several eradication regimens have been proposed over the last years with respect to the best approach to antibiotic resistance [2]. *H. pylori* infection has undoubtedly imposed a notable economic burden on European healthcare systems that has not been evaluated in detail so far [3], especially during the last decade of financial crisis. Liatsos *et al* [4] recently estimated thoroughly, for the first time in Greece, the expenditures of all available *H. pylori* eradication treatment regimens. Direct medical costs for a single-attempt outpatient *H. pylori* eradication treatment were calculated for both prototypes and generics, revealing that regimens based on pantoprazole 40 mg are the most affordable choice, followed by esomeprazole and rabeprazole. Papaefthymiou *et al* [5] published the first study evaluating the cost effectiveness of *H. pylori* treatment regimens in Greece, and suggested a 10-day concomitant regimen with generics using esomeprazole 40 mg as the most appropriate. Given these findings, one might presume that a national or international consensus could include in its statements changes in direct costs concerning first, second or salvage treatment schemes, as well as cost-effectiveness approaches based on relevant studies. Randomized studies concerning the long-term cost benefits after *H. pylori* eradication treatments seem to be necessary [6,7].

Economic evaluation seems increasingly significant as healthcare systems become more expensive, considering

the high prevalence of *H. pylori* globally. *H. pylori* treatment costs should be taken into account by the policy-makers of the existing healthcare systems. These data could also be used for the development of specific adjusted strategies for global eradication, aiming at a better as well as less expensive therapeutic approach to the patient.

References

1. Georgopoulos S, Michopoulos S, Rokkas T, et al. Hellenic consensus on *Helicobacter pylori* infection. *Ann Gastroenterol* 2020;**33**:(in press).
2. Liatsos C, Georgopoulos SD. *Helicobacter pylori* best treatment approach: should a national consensus be the best consensus? *Ann Gastroenterol* 2017;**30**:704-706.
3. EUROSTAT. Expenditure for selected health care functions by health care financing schemes. 2019. Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha11_hchf [Accessed 3 February 2020].
4. Liatsos C, Papaefthymiou A, Kyriakos N, et al. The economic cost per treatment for the *Helicobacter pylori* eradication treatment schemes in Greece. *Helicobacter* 2018;**23**(Suppl 1):e12525 (P02.24). [Abstract]
5. Papaefthymiou A, Liatsos C, Georgopoulos SD, et al. *Helicobacter pylori* eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. *Helicobacter* 2020;**25**:e12666.
6. Høgh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of *Helicobacter pylori* population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. *Aliment Pharmacol Ther* 2019;**49**:1013-1025.
7. Vakil N. Editorial: population-based testing for *Helicobacter pylori* in Western countries. *Aliment Pharmacol Ther* 2019;**49**:1360.

Department of ^aGastroenterology, 401 Army General Hospital of Athens (Christos Liatsos, Apostolis Papaefthymiou); ^bGastroenterology, Athens Medical, Paleo Faliron Hospital, Athens (Sotirios D. Georgopoulos); ^cMedicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia (Jannis Kountouras), Greece

Conflict of Interest: None

Correspondence to: Christos Liatsos, MD, PhD, FEBGH, Consultant Gastroenterologist, Director of the Gastroenterology Department, 401 General Army Hospital of Athens, Athens 11525, Greece, e-mail: cliatsos@yahoo.com

Received 22 January 2020; accepted 28 January 2020; published online 14 March 2020

DOI: <https://doi.org/10.20524/aog.2020.0462>